PIK3CA-related overgrowth: silver bullets from the cancer arsenal?
Ralitsa R Madsen, Robert K Semple, Ralitsa R Madsen, Robert K Semple
Abstract
Mutations that activate growth factor signaling often drive cancer growth. Many also arise in isolation, causing developmental growth disorders. PIK3CA, that encodes a catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is a cardinal example of this paradigm. Recent exciting progress towards the key goal of cancer drug repurposing for PIK3CA-driven overgrowth is discussed.
Trial registration: ClinicalTrials.gov NCT04589650.
Keywords: CLOVES; PI3K; PIK3CA; PROS; alpelisib; overgrowth; phosphatidylinositol 3-kinase; sirolimus; trials.
Conflict of interest statement
Declaration of interests R.K.S. has received consulting fees from Novartis and is an investigator in the Novartis-sponsored EPIK-P2 Trial. R.K.S. and R.R.M. have both received research funding from the CLOVES Syndrome Community.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Source: PubMed